Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 May;23(2-3):45-49.
doi: 10.1038/s41397-022-00295-3. Epub 2022 Oct 22.

Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder

Valentin Skryabin  1   2 , Ilya Rozochkin  3 , Mikhail Zastrozhin  3   4   5 , Volker Lauschke  6   7   8 , Johan Franck  9 , Evgeny Bryun  3   4 , Dmitry Sychev  4
Affiliations
Meta-Analysis

Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder

Valentin Skryabin et al. Pharmacogenomics J. 2023 May.

Abstract

The study aimed to conduct a meta-analysis of studies comparing pharmacogenetically guided dosing of antidepressants with empiric standard of care. Publications referring to genotype-guided antidepressant therapy were identified via PubMed, Google Scholar, Scopus, Web of Science, Embase, and Cochrane databases from the inception of the databases to 2021. In addition, bibliographies of all articles were manually searched for additional references not identified in primary searches. Studies comparing clinical outcomes between two groups of patients who received antidepressant treatment were included in meta-analysis. Analysis of the data revealed statistically significant differences between the experimental group receiving pharmacogenetically guided dosing and the empirically treated controls. Specifically, genotype-guided treatment significantly improved response and remission of patients after both eight and twelve weeks of therapy, whereas no effect on the development of adverse drug reactions was observed. This meta-analysis indicates that the use of preemptive genotyping to guide dosing of antidepressants might increase treatment efficacy.

PubMed Disclaimer

References

    1. Vilches S, Tuson M, Vieta E, Álvarez E, Espadaler J. Effectiveness of a pharmacogenetic tool at improving treatment efficacy in major depressive disorder: a meta-analysis of three clinical studies. Pharmaceutics. 2019;11:453. https://doi.org/10.3390/pharmaceutics11090453 . - DOI - PubMed - PMC
    1. van Schaik RHN, Müller DJ, Serretti A, Ingelman-Sundberg M. Pharmacogenetics in psychiatry: an update on clinical usability. Front Pharm. 2020;11:575540. https://doi.org/10.3389/fphar.2020.575540 . - DOI
    1. Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics. 2020;21:559–69. https://doi.org/10.2217/pgs-2019-0157 . - DOI - PubMed
    1. Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21:533–41. https://doi.org/10.1038/s41397-021-00249-1 . - DOI - PubMed
    1. Solomon HV, Cates KW, Li KJ. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? Psychiatry Res. 2019;271:604–13. https://doi.org/10.1016/j.psychres.2018.12.053 . - DOI - PubMed

Publication types

MeSH terms

Substances